Royalty Pharma Announces Closing of Initial Public Offering
June 18 2020 - 4:15PM
Royalty Pharma plc (NASDAQ: RPRX) today announced the closing of
the initial public offering of 89,333,920 shares of its Class A
ordinary shares pursuant to a registration statement on Form S-1
filed with the U.S. Securities and Exchange Commission (“SEC”) at a
price to the public of $28.00 per share. The size of the IPO was
increased from the previously announced 70,000,000 Class A ordinary
shares. The company offered 71,652,250 Class A ordinary
shares and the selling shareholders offered 17,681,670 Class A
ordinary shares. The number of Class A ordinary shares issued at
closing included the exercise in full of the underwriters’ option
to purchase 11,652,250 additional Class A ordinary shares from the
company. The Class A ordinary shares began trading on the
Nasdaq Global Select Market under the ticker symbol “RPRX” on June
16, 2020.
J.P. Morgan, Morgan Stanley, BofA Securities,
Goldman Sachs & Co. LLC, Citigroup and UBS Investment Bank
acted as joint lead book-running managers and as representatives of
the underwriters for the offering. Evercore ISI, Cowen and SunTrust
Robinson Humphrey also acted as joint book-running managers for the
offering. BBVA, DNB Markets, Scotiabank, TD Securities, Academy
Securities, AmeriVet Securities, Blaylock Van, LLC, Cabrera Capital
Markets LLC, R. Seelaus & Co., LLC, Ramirez & Co., Inc.,
Siebert Williams Shank and Tigress Financial Partners acted as
co-managers for the offering.
This offering was made only by means of a
prospectus. Copies of the final prospectus relating to the initial
public offering may be obtained from: J.P. Morgan Securities LLC,
Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, by telephone at 1-866-803-9204 or by email at
prospectus-eq_fi@jpmchase.com or Morgan Stanley & Co. LLC,
Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, New York 10014.
A registration statement relating to these
securities has been filed with, and was declared effective by the
SEC. Copies of the registration statement can be accessed through
the SEC's website at www.sec.gov. This news release shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Royalty PharmaFounded in
1996, Royalty Pharma is a leading funder of innovation across the
biopharmaceutical industry, collaborating with innovators from
academic institutions, research hospitals and not-for-profits
through small and mid-cap biotechnology companies to leading global
pharmaceutical companies. Royalty Pharma has assembled a portfolio
of royalties which entitles it to payments based directly on the
top-line sales of many of the industry’s leading therapies. Royalty
Pharma funds innovation in the biopharmaceutical industry both
directly and indirectly - directly when it partners with companies
to co-fund late-stage clinical trials and new product launches in
exchange for future royalties, and indirectly when it acquires
existing royalties from the original innovators. Royalty Pharma’s
current portfolio includes royalties on more than 45 commercial
products, including AbbVie and J&J’s Imbruvica, Astellas and
Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s
Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and
Trikafta, and three development-stage product candidates.
Royalty Pharma Investor Relations and
Communications:+1 (212) 883-0200ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024